Experiments show that transferring a cancer cell's dysfunctional mitochondria—but not its nucleus—into a healthy cell is what induces cancer. This disruptive finding supports the view of cancer as a metabolic disease that can be targeted by starving its mitochondria of fuels like glucose.

Many cancer cells rely heavily on glucose (the Warburg effect) and cannot efficiently use ketones. A strict ketogenic diet may starve these tumors while nourishing healthy cells. In one case, it led to a 70% reduction in cancer markers in six weeks, far exceeding chemotherapy's expected 30%.

Dr. Fred Hatfield, a famous powerlifter, reportedly achieved years of remission from metastatic prostate cancer by implementing a 'sardine fast.' This protocol involved consuming only one can of sardines per day for one week each month, similar to a fasting-mimicking diet.

Direxonrasib is showing unprecedented response rates (e.g., 47% in frontline) for metastatic pancreatic cancer, a historically difficult-to-treat disease. This high performance prompts comparisons to the targeted therapy successes seen in lung cancer, signaling a potential paradigm shift in treatment expectations for PDAC.

A novel pilot study, the TRIMM trial, is investigating if a GLP-1 agonist can eliminate minimal residual disease (MRD), as measured by ctDNA, in breast cancer patients with obesity. This frames a metabolic intervention as a potential anti-cancer therapeutic, moving beyond its role in supportive care.

Virta Health achieves high adherence by adapting its nutritional therapy to patients' real-world constraints. For a truck driver limited to McDonald's, the advice is a lettuce-wrapped burger, no ketchup, and diet soda, proving progress trumps perfection for metabolic health.

Given that standard therapies for metastatic pancreatic cancer are not curative, leading oncologists argue that clinical trials should be the primary consideration for all eligible patients. Standard chemotherapy regimens are viewed as fallback options. This approach frames trials as the best path to advancing care, not an experimental last resort.

Chemotherapy is known to worsen metabolic parameters, but this should be viewed as an opportunity, not just a side effect. By actively correcting this metabolic dysfunction with adjunctive therapies, clinicians may be able to enhance the overall life-saving benefit of the chemotherapy itself.

In a remarkable outcome, daraxin racid achieved a 13.2-month median survival for second-line pancreatic cancer patients. This survival rate is historically better than the outcomes for standard first-line chemotherapy regimens. This suggests the drug has the potential to become a foundational therapy if moved into earlier stages of treatment.